Peter Goldstein | Executive Director, Research and Development
ILIAD Biotechnologies

Peter Goldstein, Executive Director, Research and Development, ILIAD Biotechnologies

Peter Goldstein, Executive Director of Vaccine Platform Development. Peter has 18 years of experience managing multidisciplinary scientific and technical programs.  He plays a central role in management of ILiAD’s assay development, clinical serology, and Quality Management System, and is responsible for many of ILiAD’s non-pertussis indications, including Asthma and Tuberculosis.  Following his work with anti-cancer peptides in the laboratory of Nobel Laureate Andrew Schally, he co-founded Biscayne Pharmaceuticals in 2012 (later becoming Biscayne Neurotherapeutics). At Biscayne, he was responsible for R&D and Clinical Operations, managing global drug development programs in oncology and epilepsy. In these roles he oversaw clinical epilepsy trials, GMP manufacturing of peptides and small molecules, pharmacokinetics & toxicology studies in multiple species, development of novel in-vitro assays, pre-clinical oncology studies, buildout of quality systems and SOP development. He also supported due diligence and intellectual property, resulting in a successful business exit strategy.  
He began his career as a technical product manager at Ceradyne, Inc., and has overseen Phase 1-4 clinical trials in various consulting roles. Peter holds B.S. and M.S. degrees in Materials Science and Engineering from the University of Florida.


Day 1 - November 28 @ 16:50

BPZE1 Induces Serum Bactericidal Activity against Pertactin-Positive and Pertactin-Deficient B. Pertussis

last published: 02/Jan/24 12:15 GMT

back to speakers